Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

DYRK2 antibody (N-Term)

DYRK2 Reactivity: Human WB, IHC (p) Host: Rabbit Polyclonal RB3008 unconjugated
Catalog No. ABIN391770
  • Target See all DYRK2 Antibodies
    DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))
    Binding Specificity
    • 15
    • 11
    • 8
    • 7
    • 5
    • 4
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 105-135, N-Term
    Reactivity
    • 42
    • 32
    • 22
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Host
    • 55
    • 7
    • 1
    Rabbit
    Clonality
    • 56
    • 7
    Polyclonal
    Conjugate
    • 26
    • 5
    • 5
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This DYRK2 antibody is un-conjugated
    Application
    • 56
    • 33
    • 27
    • 13
    • 13
    • 8
    • 5
    • 3
    • 3
    • 2
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Purification
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This DYRK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 105-135 amino acids from the N-terminal region of human DYRK2.
    Clone
    RB3008
    Isotype
    Ig Fraction
  • Application Notes
    WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
    Expiry Date
    6 months
  • Mimoto, Imawari, Hirooka, Takeyama, Yoshida: "Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer." in: Oncogene, Vol. 36, Issue 13, pp. 1862-1872, (2017) (PubMed).

    Nomura, Suzuki, Takahashi, Terasaki, Kimata, Terasaki, Hamasaki, Kimura, Shimizu, Kondo: "Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy." in: BMC urology, Vol. 15, pp. 53, (2015) (PubMed).

    Moreno, Lara-Chica, Soler-Torronteras, Caro, Medina, Álvarez, Salvatierra, Muñoz, Calzado: "The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer." in: PLoS ONE, Vol. 10, Issue 11, pp. e0143376, (2015) (PubMed).

    Enomoto, Yamashita, Yoshinaga, Fukami, Miyahara, Nabeshima, Iwasaki: "Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer." in: Tumour biology, Vol. 35, Issue 11, pp. 11021-5, (2014) (PubMed).

    Taira, Mimoto, Kurata, Yamaguchi, Kitagawa, Miki, Yoshida: "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells." in: The Journal of clinical investigation, Vol. 122, Issue 3, pp. 859-72, (2012) (PubMed).

    Pérez, García-Limones, Zapico, Marina, Schmitz, Muñoz, Calzado: "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways." in: Journal of molecular cell biology, Vol. 4, Issue 5, pp. 316-30, (2012) (PubMed).

    Yamashita, Chujo, Tokuishi, Anami, Miyawaki, Yamamoto, Kawahara: "Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma." in: The Journal of thoracic and cardiovascular surgery, Vol. 138, Issue 6, pp. 1303-8, (2009) (PubMed).

    Yamashita, Chujo, Moroga, Anami, Tokuishi, Miyawaki, Kawano, Takeno, Yamamoto, Kawahara: "DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer." in: Anticancer research, Vol. 29, Issue 7, pp. 2753-7, (2009) (PubMed).

  • Target
    DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))
    Alternative Name
    DYRK2 (DYRK2 Products)
    Synonyms
    DYRK2 antibody, fc18c09 antibody, si:ch211-266a5.8 antibody, wu:fa09g03 antibody, wu:fc18c09 antibody, 1810038L18Rik antibody, dual specificity tyrosine phosphorylation regulated kinase 2 antibody, dual specificity tyrosine-phosphorylation-regulated kinase 2 antibody, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 antibody, DYRK2 antibody, CpipJ_CPIJ014802 antibody, dyrk2 antibody, Dyrk2 antibody
    Background
    DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro.
    Molecular Weight
    66652
    Gene ID
    8445
    NCBI Accession
    NP_003574, NP_006473
    UniProt
    Q92630
    Pathways
    Regulation of Carbohydrate Metabolic Process
You are here:
Support